News &amp; Updates

Fremanezumab 225 mg/1.5 mL solution for injection (pre-filled syringe)

Product Highlight - AJOVY

Product Highlight - ROCURONIUM B. BRAUN SOLUTION FOR INJECTION/INFUSION

Rocuronium bromide 50 mg/5 mL solution for injection/infusion

Product Highlight - ROCURONIUM B. BRAUN SOLUTION FOR INJECTION/INFUSION

Spontaneous eye blink rate a good marker of consciousness after brain injury

30 Nov 2021

In the postacute phase after brain injury, the spontaneous eye blink rate is higher in patients in a minimally conscious state and may help distinguish MCS from the vegetative state/unresponsive wakefulness syndrome, a recent study has found.

Spontaneous eye blink rate a good marker of consciousness after brain injury

30 Nov 2021

Aspirin, cilostazol exert similar effects on white matter changes in cerebral small vessel disease

The progression of white matter changes in cerebral small vessel disease does not seem to be different between aspirin- and cilostazol-treated patients, a study has found.

Aspirin, cilostazol exert similar effects on white matter changes in cerebral small vessel disease

Music plus abdominal vibrations safe but ineffective against musculoskeletal pain in older adults

The combination of music and abdominally administered vibrations is safe and well-tolerated for the treatment of musculoskeletal pain in elderly adults but shows limited efficacy, a recent study has found.

Music plus abdominal vibrations safe but ineffective against musculoskeletal pain in older adults

Sleep time: What is the golden hour for better heart health?

25 Nov 2021 by

Sleeping between 10–11 pm is associated with a decreased risk of developing cardiovascular disease (CVD) compared with earlier or later bedtimes, according to a study — suggesting that this timing represents the optimal sleeping time for better heart health.

Sleep time: What is the golden hour for better heart health?

25 Nov 2021

Focused ultrasound shows promise in drug-resistant epilepsy

24 Nov 2021

Low-intensity focused ultrasound can be delivered to the target zone in patients with drug-resistant epilepsy without significant adverse events, as shown in a phase I study. Moreover, the treatment produces meaningful changes in stereo-electroencephalography activity.

Focused ultrasound shows promise in drug-resistant epilepsy

24 Nov 2021

Original New Drug Application Approvals by US FDA (01-15 November 2021)

New drug applications approved by US FDA as of 01-15 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 November 2021)

Fenfluramine helps minimize day-to-day seizure burden in Dravet syndrome

Treatment with fenfluramine in patients with Dravet syndrome (DS) appears to produce a marked reduction in day-to-day seizure burden and provide prolonged periods of convulsive seizure-free days, as shown in a study.

Fenfluramine helps minimize day-to-day seizure burden in Dravet syndrome